Allovir Inc (ALVR)

Nov 9, 2024, 10:12 PM EST - 2 months ago

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

Nov 9, 2024, 10:26 AM EST - 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

EMKR

Nov 8, 2024, 6:00 AM EST - 2 months ago

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

Sep 16, 2024, 11:16 AM EDT - 4 months ago

Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm

Mar 19, 2024, 7:00 AM EDT - 10 months ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 17, 2024, 11:00 PM EDT - 10 months ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 11, 2024, 7:00 AM EDT - 11 months ago

MARCH 19 FINAL DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 9, 2024, 8:00 AM EST - 11 months ago

INVESTOR DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 8, 2024, 3:30 AM EST - 11 months ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 7, 2024, 5:45 AM EST - 11 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

Mar 7, 2024, 3:30 AM EST - 11 months ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 6, 2024, 1:00 PM EST - 11 months ago

MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 5, 2024, 2:15 PM EST - 11 months ago

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 4, 2024, 3:00 PM EST - 11 months ago

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm

Feb 29, 2024, 10:00 AM EST - 11 months ago

SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

Feb 21, 2024, 9:45 AM EST - 11 months ago

ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

Feb 9, 2024, 10:45 AM EST - 1 year ago

ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

Feb 6, 2024, 8:00 AM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Feb 2, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Jan 26, 2024, 8:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Jan 25, 2024, 7:00 AM EST - 1 year ago

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm

Jan 22, 2024, 11:45 PM EST - 1 year ago

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses In Excess of $100,000 to Contact the Firm

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

GRI IBIO VYNE

Jan 4, 2024, 6:20 PM EST - 1 year ago

AlloVir shedding 95% of its staff after discontinuing T cell therapy trial

Dec 22, 2023, 2:31 PM EST - 1 year ago

AlloVir's stock suffers record plunge toward a record low after trials on T cell therapy

Dec 22, 2023, 7:00 AM EST - 1 year ago

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Nov 16, 2023, 7:00 AM EST - 1 year ago

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 2, 2023, 7:00 AM EDT - 1 year ago

AlloVir Reports Third Quarter 2023 Financial Results

Aug 28, 2023, 7:00 AM EDT - 1 year ago

AlloVir to Present at Upcoming Investor Conferences

Aug 3, 2023, 7:00 AM EDT - 1 year ago

AlloVir Reports Second Quarter 2023 Financial Results

Jul 10, 2023, 7:13 PM EDT - 1 year ago

AlloVir: 'Takes One To Know One'

Jul 1, 2023, 3:48 AM EDT - 1 year ago

AlloVir: Several Late-Stage Programs Make This Worth A Look

Jun 21, 2023, 9:20 PM EDT - 1 year ago

AlloVir Announces Pricing of Public Offering of Common Stock